Just – Evotec Biologics

The journey of Just - Evotec Biologics began in 2014, when it was founded as Just Biotherapeutics in Seattle, Washington. From its inception, the company was driven by a clear and ambitious mission: to dramatically expand global access to essential biotherapeutics. The founders envisioned a future where innovative technologies could break down the scientific and economic barriers that often limit the availability of life-saving protein therapeutics. At the core of this vision was the development of an integrated technology platform, a suite of tools designed to streamline the entire biologics development process, from the initial design and lead optimization to efficient, scalable manufacturing. This early focus on technology and efficiency, particularly through the pioneering use of machine learning and data-driven approaches, set Just Biotherapeutics on a path of rapid growth and innovation. The company's potential did not go unnoticed, attracting backing from prominent investors, including the Bill & Melinda Gates Foundation, which underscored the global health implications of its mission.

A pivotal moment in the company's story came in 2019 with its acquisition by Evotec SE, a leading global drug discovery and development company headquartered in Germany. This strategic move marked the beginning of a new chapter, and the company was rebranded as Just - Evotec Biologics. The acquisition was a perfect synergy; Evotec's extensive expertise in small molecule discovery was now complemented by Just's powerful platform for biologics. As a wholly-owned subsidiary, Just - Evotec Biologics became the biologics arm of Evotec, significantly strengthening its parent company's capabilities and offerings. This integration has allowed the company to accelerate its mission on a global scale. Today, Just - Evotec Biologics continues to be a trailblazer in the industry, leveraging its proprietary J.DESIGN platform, which includes advanced AI/ML technologies and innovative continuous manufacturing processes. With its state-of-the-art J.POD® facilities in the US and Europe, the company is not just a contract development and manufacturing organization (CDMO); it is a technology powerhouse dedicated to making biotherapeutics more affordable and accessible to patients worldwide, truly embodying its founding principle of innovation for global health.